Form 4: Centessa Pharmaceuticals Acquisition Complete

Centessa Pharmaceuticals plc's acquisition by Eli Lilly and Company has been finalized, with shareholders receiving cash and contingent value rights.

Summary

• The acquisition of Centessa Pharmaceuticals plc by Eli Lilly and Company, through its subsidiary LDH XV Corporation, was completed on June 24, 2026, via a scheme of arrangement.
• Shareholders are entitled to receive $38.00 in cash per ordinary share, plus a non-transferable contingent value right (CVR) for potential additional payments up to $9.00 per share.
• These CVRs are contingent upon the achievement of specified milestones outlined in a separate agreement.
• All outstanding and unvested Restricted Share Units (RSUs) were fully vested and converted into the right to receive the cash consideration and CVR.
• Similarly, all outstanding share options were cancelled and converted into the right to receive cash equal to the excess of the cash consideration over the exercise price, plus a CVR.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for the reporting person and former shareholders, as it confirms the completion of an acquisition with a significant cash payout and potential for further upside through CVRs.

Positives

• Shareholders received a cash payment of $38.00 per ordinary share.
• Shareholders are eligible for potential future payments through contingent value rights (CVRs) of up to $9.00 per share.
• All outstanding equity awards (RSUs and options) were settled, providing value to holders.

Negatives

• The acquisition means Centessa Pharmaceuticals plc is no longer a publicly traded entity, limiting future upside for former shareholders.
• The value of the CVRs is contingent and not guaranteed, introducing uncertainty regarding the total payout.

Risks

• The realization of contingent payments from the CVRs is dependent on Eli Lilly achieving specific, undisclosed milestones.
• There is a risk that the specified milestones for the CVRs may not be met, resulting in no additional payments beyond the initial cash consideration.

Future Outlook

The future outlook for Centessa Pharmaceuticals plc as an independent entity is concluded due to the acquisition. The future value for former shareholders is tied to the contingent value rights (CVRs) which depend on Eli Lilly achieving specific milestones.

Industry Context

StockSavvy.ai notes that this Form 4 filing confirms the completion of a significant acquisition in the pharmaceutical sector, reflecting a trend of consolidation driven by larger companies seeking to expand their pipelines and market presence. The inclusion of contingent value rights is a common mechanism in such deals to bridge valuation gaps and incentivize continued development post-acquisition.

Stakeholder Impact

• Shareholders: Receive $38.00 cash per share and a contingent value right (CVR) for potential additional payments.
• Employees: Employment status and roles are now under Eli Lilly and Company, with potential changes based on integration plans.
• Management: Reporting person (Mario Alberto Accardi) has transitioned from CEO of Centessa Pharmaceuticals plc to a role within the acquired entity under Eli Lilly.

Next Steps

• Eli Lilly and Company will manage the development and potential milestone achievement related to the contingent value rights.
• Former Centessa Pharmaceuticals plc shareholders will await the outcome of the milestone achievement to determine the final value of their CVRs.

Key Dates

Keywords

Centessa Pharmaceuticals, Eli Lilly, Acquisition, Scheme of Arrangement, Form 4, SEC Filing, Contingent Value Rights, Restricted Share Units, Share Options, CNTA